{
    "clinical_study": {
        "@rank": "56874", 
        "arm_group": [
            {
                "arm_group_label": "Experimental: Arm A", 
                "arm_group_type": "Experimental", 
                "description": "OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone"
            }, 
            {
                "arm_group_label": "Control Arm: Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Continuation of standard therapy with abiraterone acetate and prednisone"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427\n      to continuing abiraterone acetate and prednisone treatment in men with metastatic\n      castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA)\n      progression"
        }, 
        "brief_title": "OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Metastatic Castrate-Resistant Prostate Cancer", 
            "PSA"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OUTLINE:  This is a multi-center study.\n\n      This is an open-label, randomized, Phase II clinical trial designed to evaluate the\n      anti-tumor effects of OGX-427 and continuing abiraterone acetate and prednisone versus\n      continuing abiraterone acetate and prednisone alone in men with MCRPC who have evidence of\n      PSA progression but no evidence of symptomatic or radiographic progression that would\n      require alternative therapy (e.g., needing radiation therapy for pain or significant\n      progression of visceral metastases).\n\n      Patients on the control arm will be allowed to cross-over to receive OGX-427 following\n      documented disease progression. Patients will be randomized with equal probability to one of\n      the following arms:\n\n      EXPERIMENTAL ARM (Arm A):\n\n      OGX-427 Starting within 7 days of randomization, three loading doses of 600 mg intravenously\n      (IV) within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly\n      doses of 800 mg IV\n\n      Continuation of standard therapy with abiraterone acetate 1000 mg by mouth (PO) daily and\n      prednisone 10-20 mg PO daily\n\n      CONTROL ARM (Arm B):\n\n      Continuation of standard therapy with abiraterone acetate 1000 mg PO daily and prednisone\n      10-20 mg PO daily\n\n      After documented disease progression, patients on Arm B may opt to receive OGX-427 treatment\n      (according to the Arm A schedule) following a screening evaluation (i.e., all inclusion and\n      exclusion criteria have been met)\n\n      Both Arms:\n\n      Evaluations at 4 week-intervals. Disease assessments required at the milestone Day 60\n      assessment (expected to occur after 8 weeks of treatment and prior to Day 1, Week 9) and at\n      16, 24, 32, 40, and 48 weeks (if applicable) or until documented disease progression.\n      Patients who are withdrawn from the study for a reason other than documented disease\n      progression or patient withdrawal of consent will be followed every 4 weeks in the\n      Off-Treatment Follow-up Period until documented disease progression.\n\n      Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n      Life Expectancy: Not Specified\n\n      Hematopoietic:\n\n        -  Absolute neutrophil count (ANC) \u2265 1.5 x 109 cells /L, platelet count \u2265 100 x 109 /L,\n           and hemoglobin \u2265 9 g/dL without transfusion\n\n      Hepatic:\n\n        -  Total bilirubin \u2264 1.1 x upper limit of normal (ULN) unless elevated secondary to\n           conditions such as Gilbert's disease, in which case a direct bilirubin \u2264 ULN is\n           required\n\n        -  Serum glutamic pyruvic transaminase (SGPT), alanine transaminase (ALT) and alanine\n           transaminase (SGOT) aspartate transaminase (AST) \u2264 3.0 x ULN\n\n      Renal:\n\n        -  Creatinine \u2264 1.3 x ULN\n\n      Cardiac:\n\n        -  Known left ventricular ejection fraction (LVEF) <50% or New York Heart Association\n           (NYHA) Functional Classification Class III or IV heart failure\n\n      Other:\n\n        -  Castrate serum testosterone level (< 50 ng/dL or < 1.7 nmol/L)\n\n        -  Potassium within normal limits"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet ALL of the following criteria to be eligible for inclusion into the\n        study.\n\n          -  Histological or cytological diagnosis of adenocarcinoma of the prostate\n\n          -  Metastatic disease on chest, abdominal, or pelvic computed tomography (CT) scan\n             and/or bone scan\n\n          -  Currently receiving abiraterone acetate and prednisone and meeting the following\n             criteria:\n\n               -  Any PSA decline within 12 weeks from initiation of abiraterone acetate\n\n               -  Currently tolerating abiraterone acetate (1000 mg oral daily) and prednisone\n                  (10-20 mg oral daily)\n\n               -  PSA progression, defined as an increase in PSA which is \u226525% above the nadir and\n                  an absolute value of \u22652 ng/mL, which is confirmed by a second value \u22652 weeks\n                  later.\n\n               -  No evidence of symptomatic or radiographic progression that would require\n                  alternative therapy (e.g., needing radiation therapy for pain or significant\n                  progression of visceral metastases or >33% increase in daily opioid use within 2\n                  weeks prior to randomization).\n\n          -  All patients who have not had a surgical orchiectomy must continue treatment with a\n             luteinizing hormone-releasing hormone (LHRH) agonist or antagonist to maintain a\n             castrate level of testosterone.\n\n          -  Patient must fulfill \"Prior Therapy\" criteria as follows:\n\n               -  Chemotherapy: no more than 1 prior chemotherapy regimen for castrate-resistant\n                  prostate cancer (CRPC) is permitted; a minimum of at least 28 days must have\n                  passed since the last dose of chemotherapy.\n\n               -  Hormone therapy: hormonal androgen ablation therapy prior to abiraterone is\n                  required.\n\n               -  Experimental therapy: prior non-cytotoxic experimental therapy is permitted\n                  provided a minimum of at least 14 days has passed since completing therapy.\n                  Prior treatment with enzalutamide (MDV3100) is allowed.\n\n               -  Radiation: prior external beam radiation is permitted provided a minimum of at\n                  least 14 days have passed since completing radiotherapy (exception for\n                  radiotherapy: at least 7 days since completing a single fraction of \u2264800 cGy to\n                  a restricted field or limited-field radiotherapy to non-marrow bearing area such\n                  as an extremity or orbit) at the time of randomization\n\n          -  Must be willing to use effective contraception throughout study treatment and for 3\n             months after completion of study treatment if able to father a child.\n\n          -  Must be willing not to change (add or subtract) bone protecting therapy\n             (bisphosphonates and/or denosumab) during the study unless changed for toxicity.\n\n          -  Written informed consent must be obtained prior to any protocol-specific procedures\n             being performed.\n\n        Exclusion Criteria:\n\n        Subjects meeting ANY of the following exclusion criteria will NOT be eligible for\n        inclusion into the study:\n\n          -  Currently receiving abiraterone acetate in combination with any other anti-cancer\n             agent (except prednisone)\n\n          -  Documented brain metastases, or carcinomatous meningitis, treated or untreated (Brain\n             imaging for asymptomatic patients is not required.)\n\n          -  Cord compression requiring surgery or radiation therapy while on abiraterone\n             treatment\n\n          -  Active second malignancy (including lymphoid malignancies such as chronic lymphocytic\n             leukemia or low grade lymphoma) defined, in general, as requiring anticancer therapy\n             or at high risk of recurrence during the study; not including adequately treated non\n             melanomatous skin cancer or other solid tumors curatively treated with no evidence of\n             disease in > 3 years\n\n          -  History of allergic reactions to therapeutic antisense oligonucleotides\n\n          -  Active autoimmune disease requiring treatment\n\n          -  Participated in a prior Phase 3 clinical study evaluating custirsen regardless of\n             study arm assignment (i.e., either control or investigational arm), or prior exposure\n             to OGX-427\n\n          -  Uncontrolled medical conditions such as myocardial infarction, uncontrolled\n             hypertension, stroke or treatment of a major active infection within 3 months of\n             randomization, as well as any significant concurrent medical illness that in the\n             opinion of the Investigator would preclude protocol therapy\n\n          -  Planned concomitant participation in another clinical trial of an experimental agent,\n             vaccine, or device. Concomitant participation in observational studies is acceptable."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681433", 
            "org_study_id": "GU12-159"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental: Arm A", 
                "description": "OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV", 
                "intervention_name": "OGX-427", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Experimental: Arm A", 
                    "Control Arm: Arm B"
                ], 
                "description": "Standard therapy: Abiraterone Acetate 1000 mg PO daily", 
                "intervention_name": "Abiraterone Acetate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Experimental: Arm A", 
                    "Control Arm: Arm B"
                ], 
                "description": "Standard therapy: Prednisone 10-20 mg PO daily", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "OGX-427", 
            "Abiraterone Acetate"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "link": {
            "description": "Hoosier Oncology Group Website", 
            "url": "http://www.hoosieroncologygroup.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "mail@prostateoncology.com", 
                    "last_name": "Mark Scholz, M.D."
                }, 
                "contact_backup": {
                    "email": "Ken@prostateoncology.com", 
                    "last_name": "Ken Chau", 
                    "phone": "310.827.7707", 
                    "phone_ext": "32"
                }, 
                "facility": {
                    "address": {
                        "city": "Marina del Rey", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90292"
                    }, 
                    "name": "Prostate Oncology Specialists, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bparsons@bloomingtonhospital.org", 
                    "last_name": "Benjamin Parsons, M.D."
                }, 
                "contact_backup": {
                    "email": "KHahn@bloomingtonhospital.org", 
                    "last_name": "Kim Hahn", 
                    "phone": "812.353.5494"
                }, 
                "facility": {
                    "address": {
                        "city": "Bloomington", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47403"
                    }, 
                    "name": "IU Health Bloomington Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "astarodub@iuhealth.org", 
                    "last_name": "Alex Starodub, M.D.", 
                    "phone": "574-535-2886"
                }, 
                "contact_backup": {
                    "last_name": "Rebecca Eickhoff, R.N.", 
                    "phone": "574.364.2649"
                }, 
                "facility": {
                    "address": {
                        "city": "Goshen", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46527"
                    }, 
                    "name": "IU Health Goshen Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "calbany@iu.edu", 
                    "last_name": "Costantine Albany, M.D.", 
                    "phone": "317-278-1711"
                }, 
                "contact_backup": {
                    "email": "kdbridge@iupui.edu", 
                    "last_name": "Kerry Bridges", 
                    "phone": "317-274-2552"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Melvin and Bren Simon Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "msgroi1@iuhealth.org", 
                    "last_name": "Madelaine Sgroi, M.D.", 
                    "phone": "317-859-5500"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46219"
                    }, 
                    "name": "IU Health Central Indiana Cancer Centers"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Taber, M.D.", 
                    "phone": "574-234-5123"
                }, 
                "contact_backup": {
                    "email": "adombkowski@beaconhealthsystem.org", 
                    "last_name": "Alicia Dombkowski", 
                    "phone": "574-647-7390"
                }, 
                "facility": {
                    "address": {
                        "city": "South Bend", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46601"
                    }, 
                    "name": "Northern Indiana Cancer Research Consortium"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christopher_sweeney@dfci.harvard.edu", 
                    "last_name": "Christopher Sweeney, M.B., B.S.", 
                    "phone": "617-632-4524"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Brian Costello, M.D.", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rlaurer@salud.unm.edu", 
                    "last_name": "Richard Laurer, M.D."
                }, 
                "contact_backup": {
                    "last_name": "Kathy Anderson", 
                    "phone": "505-925-0405"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87131"
                    }, 
                    "name": "University of New Mexico Cancer Center: Albuquerque"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mark.fleming@usoncology.com", 
                    "last_name": "Mark Fleming, M.D.", 
                    "phone": "757-213-5813"
                }, 
                "contact_backup": {
                    "email": "wendi.gobhart@usoncology.com", 
                    "last_name": "Wendi Gobhart", 
                    "phone": "757.213.5813"
                }, 
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Virginia Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dean Ruether, M.D.", 
                    "phone": "403.521.3093"
                }, 
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Alberta Health Services: Cancer Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scottnor@cancerboard.ab.ca", 
                    "last_name": "Scott North, M.D.", 
                    "phone": "780.432.8762"
                }, 
                "contact_backup": {
                    "email": "daphnewi@cancerboard.ab.ca", 
                    "last_name": "Daphne Willan", 
                    "phone": "780.432.8788"
                }, 
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kchi@bccancer.bc.ca", 
                    "last_name": "Kim Chi, M.D.", 
                    "phone": "604.877.6000", 
                    "phone_ext": "2737"
                }, 
                "contact_backup": {
                    "email": "sbrown9@bccancer.bc.ca", 
                    "last_name": "Shane Brown", 
                    "phone": "604.877.6000", 
                    "phone_ext": "2370"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BC Cancer Agency"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "joel.gingerich@cancercare.mb.ca", 
                    "last_name": "Joel Gingerich, M.D."
                }, 
                "contact_backup": {
                    "email": "heather.davies@cancercare.mb.ca", 
                    "last_name": "Heather Davies"
                }, 
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3E 0V9"
                    }, 
                    "name": "Cancer Care Manitoba"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sebastian Hotte, M.D.", 
                    "phone": "905.387.9711", 
                    "phone_ext": "64605"
                }, 
                "contact_backup": {
                    "last_name": "Diane Derosa"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fred.saad.chum@ssss.gouv.qc.ca", 
                    "last_name": "Fred Saad, M.D.", 
                    "phone": "514.890.8000", 
                    "phone_ext": "27466"
                }, 
                "contact_backup": {
                    "email": "sylvie.dagenais.chum@ssss.gouv.qc.ca", 
                    "last_name": "Sylvie Dagenais", 
                    "phone": "514.890.8000", 
                    "phone_ext": "27466"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159", 
        "other_outcome": [
            {
                "description": "Compare arms to determine the objective response of study patients.", 
                "measure": "Objective Response", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Compare arms to determine the rates of progression-free survival for study patients", 
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Compare arms to determine the time to disease progression of study patients", 
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Compare arms to determine circulating tumor cell (CTC) counts for patients at baseline and while on study", 
                "measure": "Circulating Tumor Cell (CTC) Counts", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks"
            }, 
            {
                "description": "Compare arms to determine levels of heat shock protein 27 (Hsp27), clusterin, and other relevant proteins of patients at baseline and during study", 
                "measure": "Protein Levels", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks"
            }, 
            {
                "description": "Compare arms to determine PTEN deletion status in original pathology specimens correlated with clinical outcomes", 
                "measure": "Phosphatase and tensin homolog (PTEN) Deletion Status", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks"
            }
        ], 
        "overall_contact": {
            "email": "christopher_sweeney@dfci.harvard.edu", 
            "last_name": "Christopher Sweeney, M.B., B.S.", 
            "phone": "617-632-4524"
        }, 
        "overall_contact_backup": {
            "email": "cyburkha@iupui.edu", 
            "last_name": "Cynthia Burkhardt, R.N.", 
            "phone": "317-921-2050"
        }, 
        "overall_official": {
            "affiliation": "Hoosier Oncology Group", 
            "last_name": "Christopher Sweeney, M.B., B.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To ascertain whether Arm A has a greater proportion of patients observed to be alive without progression at Day 60 (\u00b17 days) as compared to Arm B.", 
            "measure": "Progression-Free Survival", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Compare arms to determine the proportion of patients who have a PSA response (\u2265 30% decline) and any PSA decline post-randomization", 
            "measure": "PSA Response", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "source": "Hoosier Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "OncoGenex Technologies", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hoosier Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}